Matt Kaeberlein, yesterday, announced the launch of the Rapamycin Study.
They are looking for people who have previously taken rapamycin (sirolimus).
It is actively recruiting participants who will receive a unique ID and complete a series of short survey modules.
NOTE: this is not the Rapamycin Clinical Registry which is also collecting data on individuals using rapamycin.
Goal is to obtain real world data on efficacy and actual side effects associated with off-label use of rapamycin.
Although retrospective, rather than a gold-standard randomized clinical trial, it will include a non-rapamycin group for comparison.
The results will be published in peer-reviewed scientific literature and could help in design of clinical trials for age-related indications.
Matt Kaeberlein is a professor in the Department of Laboratory Medicine and Pathology, University of Washington, and also the Director of the Healthy Aging and Longevity Research Institute.
For more details, visit the study's website: https://rapamycinstudy.org
